Ownership and insider activity for Spyre Therapeutics, Inc. (SYRE): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD.
Price
| Price | $91.17 |
| Market Cap | $7.9B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-01 | King-Jones Heidy | M-Exempt | 27,999 | $406K |
| 2026-09-02 | King-Jones Heidy | M-Exempt | 400 | $6K |
| 2026-09-01 | King-Jones Heidy | M-Exempt | 27,999 | $406K |
| 2026-09-01 | King-Jones Heidy | S-Sale | 4,845 | $419K |
| 2026-09-01 | King-Jones Heidy | S-Sale | 16,548 | $1.4M |
| 2026-09-01 | King-Jones Heidy | S-Sale | 6,206 | $547K |
| 2026-09-02 | King-Jones Heidy | M-Exempt | 400 | $6K |
| 2026-09-01 | King-Jones Heidy | S-Sale | 400 | $36K |
| 2026-09-02 | King-Jones Heidy | S-Sale | 400 | $36K |
| 2026-09-01 | Burrows Scott L | M-Exempt | 7,500 | $109K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $47.7M | $12.8M | $22.5M | $19.3M | $90.1M | $15.1M | $34.9M | $188.9M | $89.4M | $85.7M |
| Short-term Investments | $15.8M | $37.5M | $52.1M | $52.7M | $56.2M | $78.0M | $20.8M | $150.4M | $513.7M | $670.8M |
| Receivables | $1.2M | $3.1M | 0 | 0 | 0 | $815000 | $375000 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $66.4M | $55.0M | $76.7M | $74.5M | $149.8M | $98.9M | $62.3M | $341.5M | $608.5M | $777.8M |
| Property, Plant & Equipment | $599000 | $854000 | $1.0M | $7.1M | $9.9M | $8.4M | $6.7M | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $67.1M | $56.1M | $77.7M | $83.2M | $161.6M | $109.9M | $71.1M | $341.9M | $608.5M | $777.8M |
| Accounts Payable | $168000 | $389000 | $663000 | $3.2M | $2.3M | $3.3M | $677000 | $896000 | $666000 | $8.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $4.0M | $5.6M | $10.2M | $18.4M | $16.4M | $20.1M | $14.7M | $32.0M | $54.1M | $58.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $4.1M | $5.7M | $10.3M | $23.1M | $21.8M | $26.0M | $20.8M | $157.8M | $90.7M | $62.5M |
| Retained Earnings | -$45.3M | -$72.5M | -$116.9M | -$195.1M | -$276.0M | -$341.8M | -$425.6M | -$764.4M | -$972.4M | -$1.13B |
| Total Equity | $63.0M | $50.3M | $67.4M | $60.1M | $139.8M | $83.9M | $50.3M | $184.0M | $517.8M | $715.2M |
| Total Debt | 0 | 0 | 0 | $5.1M | $5.4M | $5.1M | $4.6M | 0 | 0 | 0 |
| Net Debt | -$63.5M | -$50.3M | -$74.5M | -$66.9M | -$140.8M | -$88.1M | -$51.1M | -$339.3M | -$603.1M | -$756.5M |
| Working Capital | $62.5M | $49.4M | $66.4M | $56.1M | $133.3M | $78.7M | $47.6M | $309.6M | $554.4M | $719.1M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 18.53 |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | -222.49% |
| Net Margin | -197.71% |
Related companies: ABCL · ARDX · CLDX · IMNM · MAZE · NTLA · PHVS
Explore sector: Healthcare · Biotechnology
More sections of SYRE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks